Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | HTT | P42858 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 6/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.54 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963200 | 0.84 | IRAK4 (0.64) | ALDH1A1LMNAKAT2BBAZ2BGAA | |
| SCHEMBL22987538 | 0.83 | CTSD (0.62) | SMN1; SMN2ALDH1A1HTTLMNAALPL | |
| SCHEMBL29646356 | 0.83 | CTSD (0.62) | SMN1; SMN2ALDH1A1HTTLMNAALPL | |
| SCHEMBL16618453 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1HTTLMNAALPL | |
| SCHEMBL17206370 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1HTTLMNAALPL | |
| SCHEMBL1856862 | 0.81 | SLC6A3 (0.56) | SMN1; SMN2ALDH1A1HTTLMNAALPL | |
| SCHEMBL1286684 | 0.80 | IRAK4 (0.53) | SMN1; SMN2ALDH1A1HTTLMNAALPL | |
| SCHEMBL11212937 | 0.80 | HTT (0.49) | SMN1; SMN2ALDH1A1HTTLMNAALPL | |
| SCHEMBL2646539 | 0.80 | KAT2B (0.57) | SMN1; SMN2KAT2BBAZ2BGAANPC1 | |
| SCHEMBL7860488 | 0.79 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1HTTLMNAALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011512395-A | — | — | 2011-04-21 | — | — | JP | claimed |
| EP-2262504-A1 | COMBINATION THERAPY 238 | AstraZeneca AB (SE) | 2010-12-22 | — | — | EP | claimed |
| WO-2009104019-A1 | COMBINATION THERAPY 238 | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | WO | claimed |
| US-9102670-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-20140135315-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8435985-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | MENEAR KEITH (GB) | 2013-05-07 | — | — | US | disclosed |
| WO-2012074469-A1 | NEW IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| EP-2217234-A2 | COMBINATIONS OF MEK INHIBITORS WITH MTOR INHIBITORS | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| CN-101558067-A | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors | KUDOS PHARM LTD (GB) | 2009-10-14 | — | — | CN | disclosed |
| WO-2009050506-A2 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | SMN1; SMN2 3788/4885ALDH1A1 2203/4885HTT 2231/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | SMN1; SMN2 3788/4885ALDH1A1 2203/4885HTT 2231/4885 |
| US-20140135315-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | SMN1; SMN2 2237/4885ALDH1A1 1475/4885HTT 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.